Why participate?
Conduct an overview of adoptive cell therapy technologies and carry out a critical and realistic analysis
Training Context:
The CAR T-cell technology has experienced rapid growth thanks to outstanding clinical results. To date, 11 CAR T-cell products are on the market, with many more in development. However, the limitations of the technology are well known: what are the strategies to overcome these challenges? What is the current clinical track record? What can we expect from CAR T-cells in the years to come? This training explores these key questions.
Interactive Teaching, Case Studies, Experience Sharing
CEOs, CSOs, R&D managers, project managers, researchers, engineers, technicians, business developers, CROs, CDMOs, technology providers
Solid knowledge of biotechnology and immunology, or completion of the “Fundamentals of Gene Therapy” training
Prices: Excluding tax, as the training is not subject to VAT.
In-house training rate: Please contact us.
Registering online or by e-mail is a pre-registration. We will process your request within one week:
Signing the training agreement commits the company or individual to the training course. Cancellation conditions are specified in the training agreement.
When no session date is specified, pre-registration allows us to note your interest in a programme, and we will keep you informed as soon as a new session is organised.
For more information, contact Daphné Brisard: 02 47 36 63 18 or formation@mabdesign.fr
